3B Future Health Fund
Venture Capital
Active
Luxembourg, Luxembourg
32
19M
19
4.00
5
0.41
3
- Stages of investment
- Areas of investment
Summary
The fund has exact preference in a number of founders of portfolio startups. Among the most successful fund investment fields, there are Health Care, Biometrics. Among the various public portfolio startups of the fund, we may underline OncoResponse, On Target Laboratories, Personal Genome Diagnostics (PGD) Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
The common things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 23 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Helsinn Investment Fund performs on 15 percentage points less the average number of lead investments. The increased amount of exits for fund were in 2019. The top activity for fund was in 2018. The fund is constantly included in 2-6 investment rounds annually.
The usual cause for the fund is to invest in rounds with 4 partakers. Despite the Helsinn Investment Fund, startups are often financed by VI Partners AG, High-Tech Gru00fcnderfonds, Boehringer Ingelheim Venture Fund. The meaningful sponsors for the fund in investment in the same round are Windham Venture Partners, VI Partners AG, Schroder Adveq. In the next rounds fund is usually obtained by VI Partners AG, Schroder Adveq, RiverVest.
We also calculated 2 valuable employees in our database.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 32
- Lead investments
- 5
- Exits
- 3
- Rounds per year
- 4.00
- Follow on index
- 0.41
- Investments by industry
- Biotechnology (30)
- Therapeutics (15)
- Health Care (14)
- Biopharma (12)
- Medical (10) Show 13 more
- Investments by region
-
- United States (13)
- Switzerland (4)
- United Kingdom (7)
- Italy (4)
- France (2) Show 1 more
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 20M
- Group Appearance index
- 0.84
- Avg. company exit year
- 7
- Avg. multiplicator
- 8.15
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Ecometrica | 29 Sep 2008 | Supply Chain Management, Software, Information Technology, SaaS, Sustainability, Geospatial | Seed | 685K | United Kingdom, Scotland, City of Edinburgh |
| Gain Therapeutics | 19 Feb 2019 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 2M | United States, Maryland, Bethesda |
| iOnctura | 20 Jun 2024 | Biotechnology, Health Care, Medical Device | Early Stage Venture | 94M | Switzerland, Geneva, Geneva |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.